Synthetic peptide corresponding to the sequence near the N-terminus of mouse cannabinoid receptor CB1.
UniProt ID:
P47746
Species reactivity:
Human, Mouse, Rat Chicken
Crossreactivity:
Predicted species reactivity based on epitope sequence homology: gorilla, guinea pig, horse, dog, cat, platypus, Zebra Finch (bird).
Applications:
WB
Application Notes:
Predicted MW of ~53kDa. Higher MW species may also be observed by Western blot which reflect post-translational modification of the receptor.
Purity Detail:
Peptide affinity purified.
Formulation:
Liquid. In PBS containing 50% glycerol and 0.01% sodium azide.
Handling:
Keep on ice at all times.
Shipping:
Shipped on Blue Ice
Long Term Storage:
-20°C
Scientific Background:
The cannabinoid receptors CB1 and CB2 are members of the seven-transmembrane family of G-protein coupled receptors (GPCRs), and are named for their signaling function in response to cannabinoid drugs such as delta 9- tetrahydrocannabinol (delta 9-THC). CB1 and CB2 differ significantly in the length of their extracellular amino terminal domain, which is longer in CB1 (116 residues) than in CB2 (33 residues). The CB1 receptor is expressed primarily in the brain and neuronal tissue, and is highly conserved, exhibiting 97-98% amino acid sequence identity across human, mouse, and rat species. In contrast, expression of the CB2 receptor is absent in normal nervous tissue, with expression most prominent in immune tissue such as the spleen. In addition to delta 9-THC and its synthetic analogs, CB1 and CB2 receptors are bound by endogenous eicosanoid ligands, and signal via Gi/o proteins to regulate adenylyl cyclase activity (generally inhibitory), ion channel activation, intracellular Ca2+ levels, nitric oxide synthase activation, and immediate early gene expression. CB1 and CB2 signals in turn regulate neurological and immunological functions such as inhibition of neurotransmitter release and immune cell migration, antigen processing, and cytokine production.
Manufacturer:
Manufactured by Proteimax.
Western blot analysis: MW marker (1,4); 20µg CB1-expressing HEK293 cell lysate (2); 20µg CB2-expressing HEK293 cell lysate (3); 20µg rat brain extract (5); probed simultaneously with Cannabinoid Receptor (CB1) pAb, DY-682 (red) and Cannabinoid Receptor (CB2) pAb, DY-800 (green) at 0.1µg/ml. Odyssey detection – simultaneous 700nm (CB1) and 800nm (CB2). CB1 and CB2 antibodies are available either as DY-682 or DY-800 conjugates.
